ELYM实时信号 | 通过Getagraph.com最大化利润

Live Chart Being Loaded With Signals

Commentary (4 May 2024 @ 04:00):

Stats
今日成交量	1.47M
平均成交量	824 787
市值	281.54M
EPS	$0 ( 2024-04-01 )
下一个收益日期	( $0 ) 2024-05-09
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-7.81
ATR14	$0.0830 (0.82%)

Insider Trading

Date	Person	Action	Amount	type
2024-04-05	Morisset Valerie	Buy	17 847	Common Stock
2024-04-05	Morisset Valerie	Sell	17 847	Stock Option (Right to Buy)
2024-03-18	Pimblett Emily	Buy	40 000	Restricted Stock Units
2023-09-20	Morisset Valerie	Buy	15 297	Common Stock
2023-09-20	Morisset Valerie	Buy	5 431	Common Stock

INSIDER POWER
39.66
Last 75 transactions
Buy: 17 601 902 \| Sell: 12 020 423

音量相关性

長: -0.11 (neutral)

短: -0.94 (very strong negative)

Signal:(35.36) Neutral

Eliem Therapeutics, Inc. 相关性

10 最正相关
BNIXU	0.883
DFPH	0.864
THCP	0.849
VOSOU	0.842
ANZUU	0.84
CSTE	0.835
HCCC	0.831
LWAC	0.822
NISN	0.821
TMTS	0.82

10 最负相关
GIAC	-0.875
GOODM	-0.847
CTAC	-0.817
CMLT	-0.815
PRSR	-0.814
VAXX	-0.808
RMRM	-0.801

你知道吗？

相关性是描述两个变量之间关系的统计指标。它的取值范围为-1到1，其中-1表示完全负相关（一个变量增加，另一个变量减少），1表示完全正相关（一个变量增加，另一个变量也增加），0表示没有相关性（变量之间没有关系）。

相关性可用于分析任何两个变量之间的关系，而不仅仅是股票。它通常用于金融、经济学、心理学等领域。

Eliem Therapeutics, Inc. 相关性 - 货币/商品

0.49
( neutral )

0.19
( neutral )

-0.67
( moderate negative )

0.46
( neutral )

0.81
( strong )

Eliem Therapeutics, Inc. 财务报表

Annual	2023
营收:	$0
毛利润:	$0 (0.00 %)
EPS:	$-1.300

FY	2023
营收:	$0
毛利润:	$0 (0.00 %)
EPS:	$-1.300

FY	2022
营收:	$0
毛利润:	$0 (0.00 %)
EPS:	$-1.720

FY	2021
营收:	$0.00
毛利润:	$0.00 (0.00 %)
EPS:	$-3.05

Financial Reports:

No articles found.

Eliem Therapeutics, Inc.

Eliem Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing therapies for neuronal excitability disorders to address unmet needs in chronic pain, neuropsychiatry, epilepsy, and other disorders of the peripheral and central nervous systems. Its two lead drug candidates are ETX-810 for chronic pain, which is in Phase IIa clinical trial; and ETX-155 for the treatment of major depressive disorder, perimenopausal depression, and focal onset seizures that is in Phase I clinical trial. The company also develops preclinical pipeline programs, such as Kv7 Program for pain, epilepsy, and depression; and Anxiolytic for the treatment of generalized anxiety disorder. Eliem Therapeutics, Inc. was incorporated in 2018 and is headquartered in Redmond, Washington.

实时更新： Eliem Therapeutics, Inc. [ELYM]

Upcoming Earnings Alert